GWP42003-P
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Tuberous Sclerosis Complex
Conditions
Tuberous Sclerosis Complex, Seizures
Trial Timeline
Aug 31, 2016 → Jun 11, 2021
NCT ID
NCT02544750About GWP42003-P
GWP42003-P is a phase 3 stage product being developed by Jazz Pharmaceuticals for Tuberous Sclerosis Complex. The current trial status is completed. This product is registered under clinical trial identifier NCT02544750. Target conditions include Tuberous Sclerosis Complex, Seizures.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04485104 | Phase 3 | Terminated |
| NCT04133480 | Approved | Withdrawn |
| NCT04252586 | Phase 3 | Terminated |
| NCT02954887 | Phase 3 | Completed |
| NCT02953548 | Phase 3 | Completed |
| NCT02607904 | Phase 2 | Completed |
| NCT02544750 | Phase 3 | Completed |
Competing Products
13 competing products in Tuberous Sclerosis Complex
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Everolimus (RAD001) + Everolimus Placebo | Novartis | Phase 3 | 77 |
| Everolimus + Placebo | Novartis | Phase 3 | 77 |
| RAD001 | Novartis | Phase 1/2 | 41 |
| Placebo + Everolimus (RAD001) | Novartis | Phase 2 | 52 |
| RAD001 + Placebo | Novartis | Phase 2 | 52 |
| RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase) | Novartis | Phase 3 | 77 |
| Everolimus | Novartis | Phase 1/2 | 41 |
| everolimus (RAD001) | Novartis | Phase 1/2 | 41 |
| everolimus | Novartis | Phase 3 | 77 |
| sirolimus | Pfizer | Phase 2 | 51 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 74 |
| GWP42003-P + Placebo | Jazz Pharmaceuticals | Phase 3 | 74 |
| Cannabidiol Oral Solution [Epidiolex] | Jazz Pharmaceuticals | Approved | 82 |